<DOC>
	<DOC>NCT00048152</DOC>
	<brief_summary>This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patients greater than 18 years of age recipients of primary kidney transplant singleorgan recipients (kidney only) previous treatment with Zenapax history of malignancy (except localized skin cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>